Biogen announced on April 20, 2026, a significant strategic acquisition, securing exclusive rights to TJ Biopharma’s novel anti-CD38 immunotherapy, felzartamab,…
Read More

Biogen announced on April 20, 2026, a significant strategic acquisition, securing exclusive rights to TJ Biopharma’s novel anti-CD38 immunotherapy, felzartamab,…
Read More
Researchers from the Center for Nuclear Energy in Agriculture at the University of São Paulo (CENA-USP) have identified multiple classes…
Read More
A telehealth startup, MEDVi, recently lauded by The New York Times as a prime example of an AI-driven billion-dollar enterprise,…
Read More
Recent scientific investigations have unveiled a concerning correlation between the pervasive presence of microplastics in the environment and the rising…
Read More
In an era increasingly shaped by the transformative power of artificial intelligence, a Los Angeles-based telehealth startup, MEDVi, has captured…
Read More
A groundbreaking device, dubbed a "living pharmacy," capable of producing multiple therapeutic agents simultaneously within the body, has demonstrated significant…
Read More
The pervasive presence of microplastics in the global environment has long been a concern for marine biologists and ecologists, but…
Read More
Johnson & Johnson’s (J&J) groundbreaking cancer immunotherapy, Darzalex (daratumumab), has achieved a pivotal milestone in its European market penetration with…
Read More
The long-held cultural stereotype of the "forgetful stoner" has found a robust scientific foundation in a comprehensive new study from…
Read More
In a significant breakthrough for antibiotic discovery, scientists have elucidated the sophisticated mechanisms by which bacteriophages, viruses that infect bacteria,…
Read More